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Thilo Hackert, MD, and Markus W. Büchler, MDObjective: The aim of this study was to analyze the impact of teres ligament
covering on pancreatic fistula rate after distal pancreatectomy (DP).
Background: Postoperative pancreatic fistula (POPF) represents the most
significant complication after DP. Retrospective studies suggested a benefit of
covering the resection margin by a teres ligament patch.
Methods: This prospective randomized controlled study (DISCOVER trial)
included 152 patients undergoing DP, between October 2010 and July 2014.
Patients were randomized to undergo closure of the pancreatic cut margin
without (control, n¼ 76) or with teres ligament coverage (teres, n ¼ 76). The
primary endpoint was the rate of POPF, and the secondary endpoints included
postoperative morbidity and mortality, length of hospital stay, and readmis-
sion rate.
Results: Both groups were comparable regarding epidemiology (age, sex,
body mass index), operative parameters (OP time, blood loss, method of
pancreas transection, additional operative procedures), and histopathological
findings. Overall inhospital mortality was 0.6% (1/152 patients). In the group
of patients with teres ligament patch, the rate of reoperations (1.3% vs 13.0%;
P¼ 0.009), and also the rate of readmission (13.1 vs 31.5%; P¼ 0.011) were
significantly lower. Clinically relevant POPF rate (grade B/C) was 32.9%
(control) versus 22.4% (teres, P ¼ 0.20). Multivariable analysis showed teres
ligament coverage to be a protective factor for clinically relevant POPF (P ¼
0.0146).
Conclusions: Coverage of the pancreatic remnant after DP is associated with
less reinterventions, reoperations, and need for readmission. Although the
overall fistula rate is not reduced by the coverage procedure, it should be
considered as a valid measure for complication prevention due to its clinical
benefit.
Keywords: coverage, covering technique, distal pancreatectomy, morbidity,
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Annals of Surgery  Volume 264, Number 5, November 2016P ancreatic resections can be carried out with low mortality in high-volume institutions today,1 but postoperative pancreatic fistula
(POPF) remains the most important reason for postoperative morbid-
ity. Although distal pancreatectomy (DP) is a technically rather
simple procedure in most cases, safe closure of the pancreatic
remnant persists to be a main issue of this operation. The frequency
of POPF was described to be 35% in large series.2,3 During the past
decade, several surgical techniques for secure closure of the pan-
creatic remnant failed to decrease this high incidence.4–7 One
randomized trial and 4 retrospective series,5,8–11 including 1 pro-
spective study of the authors’ institution12 that were using coverage
procedures, have shown encouraging results with regard to
POPF prevention.
The aim of the DISCOVER trial was to evaluate the technique
of remnant-coverage by use of a teres ligament patch for preventing
POPF and relevant complications in a monocentric randomized
controlled trial.
METHODS
The protocol of the DISCOVER trial was registered (German
Clinical Trials Register: DRKS00000546) and published to ensure
the transparency of the design and analysis procedures, after approval
by the Ethics Committee of the University of Heidelberg.17 The trial
was conducted at the Clinical Trial Center (KSC) of the Department
of General, Visceral, and Transplantation Surgery at the University
Hospital Heidelberg. The statistical design, data management, and
analysis were performed independently at the Institute of Medical
Biometry and Informatics (IMBI) of the University of Heidelberg.
Participants
Adult patients planned for elective, open DP for benign or
malignant tumors, chronic pancreatitis, or pseudocysts of the pan-
creatic body or tail were eligible after giving informed consent. The
exclusion criteria were participation in another interventional trial,
current immunosuppressive therapy, or lack of compliance.17
Randomization
After they had given informed consent, the patients were
randomized intraoperatively after confirming the indication for DP
by the attending surgeon. Unstratified block randomization was per-
formed with random block sizes in a 1:1 allocation ratio. A random list
was generated using the PROC PLAN feature of SAS software (Cary,
NC) by the IMBI. The random allocation sequence was implemented
by the use of sequentially numbered opaque envelopes. The random-
ization process and assignment of participating patients to the trial
intervention were performed by staff members of the KSC.
Intervention
After laparotomy and exploration of the abdominal cavity,
assessing resectability and randomization, the pancreatic body andwer Health, Inc. All rights reserved.
tail were mobilized and the transection site was defined. Afterwards,
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stapler based on the observation that both of these methods are
equally effective with regard to POPF rate.6 In case of scalpel
transection, the pancreatic duct was identified and closed by crossing
stitches. The dorsal and ventral edges of the resection margin were
adapted using single stitches. Use of fibrin glue, meshes, or other
additional methods for closing or covering of the pancreatic remnant
was not allowed. An additional splenectomy or cholecystectomy was
based on the surgeon’s decision. Extended DP (vascular/additional
organ resection) did not conflict with the protocol.
In the control group, DP was performed as described above
without further coverage of the pancreatic remnant.
In patients randomized for coverage of the remnant pancreas,
the teres ligament, together with the surrounding falciform ligament,
was completely mobilized from the abdominal wall, brought to the
resection margin through an opening of the lesser omentum, and
fixed by an anterior and posterior suture line to entirely cover the
pancreatic cut margin.
At the end of the operation, 2 passive drainage tubes were
placed at the pancreatic remnant. Drainages were removed if the
amount of fluid did not exceed 200 mL/d, pancreatic enzyme con-
centrations had normalized, and no bile or blood was present in the
fluid. All drains were kept in situ for at least 3 days postoperatively.
Objectives and Outcomes
The primary endpoint was the occurrence of POPF (any grade)
as per the definition of the International Study Group on Pancreatic
Fistula (ISGPF).13 Briefly, grade A fistulas were defined as clinically
asymptomatic without any further therapeutic consequences or
POPF-related complications. Patients with parenteral nutrition, anti-
biotics, endoscopic stenting, or need for readmission were classified
as grade B. Patients requiring a POPF-associated interventional
drainage postoperatively were classified as grade C.14 Patients with
POPF-associated postoperative bleeding [postpancreatectomy hem-
orrhage (PPH)] leading to angiographic or surgical reintervention,
and also all other POPF-associated reoperations were also classified
as grade C. The interventional POPF management was standardized
in both groups and depended on the individual course.
Secondary endpoints were operation time, selected postoper-
ative complications [wound infection, delayed gastric emptying
(DGE),15 PPH,16 abdominal rupture, intra-abdominal collections,
operative or interventional revisions], inhospital mortality, duration
of hospital stay, and need for readmission. Detailed definitions of the
secondary endpoints are given in the protocol.17 An additional
analysis of treatment costs that also considered readmissions was
performed. The information of treatment costs was provided by the
financial controlling department of the authors’ institution.
Assessment of endpoints, adverse events (AEs), and serious AEs
(SAEs) was done during postoperative ward visits by members of the
KSC of the surgical department. On postoperative day 40, all patients
underwent a phone interview to obtain information about further treat-
ment or need for readmission elsewhere. In a final follow-up 1 year
postoperatively, the local hospital patient database was searched for
readmissions or reoperations associated with the initial operation.
Sample Size Calculation
The study was designed as a monocenter, randomized con-
trolled superiority trial with 2 parallel treatment arms comparing an
additional reinforcement of the pancreatic remnant by coverage with
a teres ligament patch versus stapler or suture closure alone for
preventing POPF after elective DP. The expected POPF rate of 16%
in the experimental group (teres ligament patch) was based on the
results of 1 randomized trial and 4 retrospective case series5,8–11 in Copyright © 2016 Wolters Kluw
which coverage of the pancreatic remnant was performed and the
724 | www.annalsofsurgery.cominternationally accepted definition of POPF according to ISGPF was
used. The POPF rate in the control group was expected to be 36%
based on the 30-day follow-up results of the large multicenter,
randomized DISPACT trial in which no group received additional
coverage.6 With alpha¼ 5% and beta¼ 20%, a sample size of n¼ 75
per group was necessary to detect a difference between the 2 groups
when the chi-square test (2-sided analysis) is used. In addition, a
logistic regression model including covariates of prognostic import-
ance [age, body mass index (BMI), and extent of resection] was
applied in confirmatory analysis.
Statistical Analysis
Final analyses were done in accordance with the intention-
to-treat principle. A binary logistic regression model was applied
to compare POPF rates in the 2 groups, adjusting for age, BMI,
and extent of resection. The secondary endpoints were analyzed
descriptively by calculation of adequate measures of the empirical
distribution, and also descriptive P values (result of t tests in case
of continuous data, of chi-square tests in case of categorical data)
and associated 95% confidence intervals (CIs). A post hoc
analysis was done to detect possible risk factors affecting the
development of a pancreatic fistula. A binary logistic regression
model was used with primary endpoint as a dependent variable.
Two-sided P values were used throughout (SAS Version 9.4, SAS
Institute Cary, NC). If DP was not possible or a total pancrea-
tectomy was performed after randomization, these patients were




Between October 2010 and July 2014, 161 patients were
randomized. Nine patients had to be excluded because inclusion
criteria were not met after randomization. Thus, the modified
intention-to-treat population consisted of 152 patients (coverage
procedure n ¼ 76, controls n ¼ 76; Fig. 1). Baseline characteristics
were equally distributed between both groups (Table 1).
Primary Endpoint
Patients without additional coverage after DP developed a POPF
of any grade in 39 cases (51.3%), whereas patients randomized for
additional coverage with teres ligament patch developed a POPF of any
grade in 36 cases (47.4%). No significant difference could be detected in
the univariate analysis with the chi-square test (P¼ 0.6265). The binary
logistic regression model adjusting for age, BMI, and extent of resection
showed younger patients to be at a higher risk for POPF development (P
¼ 0.03), whereas the coverage procedure was not a significant factor
[odds ratio (OR) 0.821, 95% CI 0.38–1.773].
Clinically relevant POPF (grade B/C) occurred in 17 patients
with and 25 patients without coverage procedure (grade B: n¼ 6 vs n
¼ 4; grade C: n¼ 11 vs n¼ 21), resulting in a 10% reduction of grade
B/C POPF by teres ligament coverage (P ¼ 0.1468; Fig. 2).
Secondary Endpoints
Patients without coverage had significantly more postoper-
ative reinterventions (interventional drainage procedure, angio-
graphic bleeding control, endoscopy for stent placement,
operative revision; 35.5% vs 19.7%; P ¼ 0.03; Table 2). These
differences were even more pronounced in the subgroup analysis of
POPF patients (Table 3). Seven out of 9 reoperated controls with
POPF had fistula-related reasons for revision, whereas only 1
patient from the study group had to be reoperated due to fistula-er Health, Inc. All rights reserved.
associated complications.
 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. Trial profile.
Annals of Surgery  Volume 264, Number 5, November 2016 The DISCOVER Randomized Controlled TrialReadmission was necessary significantly more often in control
patients (31.6% vs 13.2%; P ¼ 0.006), including 20 readmissions
later than postoperative day 40 (Table 2).
There were no differences in operation time, the rate of wound
infections, DGE, PPH, and incidence of abdominal rupture. Overall
mortality was 0.6%, with 1 patient in the control group who died after
apoplectic stroke on postoperative day 14 (Table 2).
Mean amylase levels and mean volume of drainage fluid
showed no differences on postoperative days 1 to 4 between both
groups. When comparing the maximum amylase value, covered
patients showed significantly lower values (7444 vs 18083 U/L; P
¼ 0.011). Furthermore, in patients who required interventional drain
placement, maximum amylase values were significantly lower in
covered patients in the fluid obtained during drainage (15321 vs
55203 U/L; P ¼ 0.03).
Exploratory multivariable analysis including potential risk
factors for POPF confirmed that age (P¼ 0.0055), length of hospital
stay (P ¼ 0.0149), and a resection level left of the portal vein
correlated with an increased risk of POPF (P ¼ 0.0448; Supple-
mentary material, Table 4, http://links.lww.com/SLA/B59).
Analysis of factors associated with POPF grade B and C,
performed by a stepwise logistic regression analysis with a forward
selection of correlating factors, revealed that the coverage procedure (P
¼ 0.0146) was a protective factor from developing a POPF of grade B or
C (Supplementary material, Table 5, http://links.lww.com/SLA/B59).
Total inpatient treatment costs were calculated including
expenses for readmissions. Analysis of POPF patients revealed
significantly lower median treatment costs in patients with coverage
compared with controls (Table 3).
DISCUSSION
Distal pancreatectomy is associated with low mortality, but Copyright © 2016 Wolters Klu
POPF remains the most important complication with an incidence of
 2016 Wolters Kluwer Health, Inc. All rights reserved.approximately 35%,2,3 with potential consequences for patients in
terms of the need for reinterventions, length of hospital stay, and
readmissions. In addition, these complications are a relevant burden
in terms of healthcare costs.12,18
In the present randomized controlled trial, the effect of cover-
age of the pancreatic remnant with a teres ligament patch on relevant
clinical complications—including POPF—was investigated. The
teres ligament patch is an easily applicable surgical procedure during
DP. The postoperative course revealed major differences between
patients with and without coverage, with significantly more operative
and nonoperative reinterventions, and also readmissions when no
coverage was performed. Although the primary endpoint of the study
(POPF incidence) did not show significant differences between the
groups, the multivariable analysis revealed that the coverage pro-
cedure was a protective factor with regard to clinically relevant POPF
development. This observation raises the question, if POPF incidence
is an adequate primary endpoint in the design of surgical studies on
DP, although it has been widely used in the past.5,6,8,11,12 The present
study shows that other endpoints (ie, reintervention, readmission) are
highly relevant for patient outcome as well, and that the more
complicated postoperative course of fistula patients without coverage
procedure does not result in a significantly different distribution of
fistula grades, rated by the ISGPF definition.13 Especially with
regard to grade C POPF, this becomes evident as patients with
POPF-associated prolonged intensive care treatment and need for
recurrent surgery cannot be distinguished from patients receiving
interventional drainage without further complications as a very
common type of management in grade C POPF. Both types of
management fulfill the prerequisites for grade C according to the
current definition which was used in the present study. A proposed
adaptation of the fistula definition rating interventional managed
cases as grade B could help to improve accuracy of the clinical
14wer Health, Inc. All rights reserved.
grading in these patients.
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TABLE 1. Patient Characteristics (mITT)
Coverage (n ¼ 76) No coverage (n ¼ 76) Total (N ¼ 152) P
Age (yrs, median, range) 65 (29–85) 67.5 (35–85) 66 (29–85) 0.119
Sex 1
Male 34 (44.7%) 34 (44.7%) 68 (44.7%)
Female 42 (55.3%) 42 (55.3%) 84 (55.3%)
BMI, kg/m2 24.7 25.8 25.1 0.418
Indication for operation
Malignant tumor 29 (38.2%) 34 (44.7%) 63 (41.4%) 0.414
Adenocarcinoma 24 25 49
IPMN carcinoma 2 3 5
Malignant neuroendocrine 1 0 1
Others 2 6 8
Benign tumor 35 (46.1%) 31 (40.8%) 66 (43.4%) 0.516
Cystadenoma 6 11 17
IPMN 6 10 16
Benign neuroendocrine 16 6 22
Others 7 4 11
Chronic pancreatitis 11 (14.5%) 6 (7.9%) 17 (22.4%) 0.201
Others 1 (1.3%) 5 (6.6%) 6 (3.9%) 0.098
Renal diseases 5 (6.6%) 7 (9.2%) 12 (7.9%) 0.547
Pulmonal disease 14 (18.4%) 11 (14.5%) 25 (16.4%) 0.512
Spirometric examination
VC (compared with age-matched group) 93% 88.7% 90.1% 0.994
FEV1 (compared with age-matched group) 95.7% 95.8% 95.8% 0.635
History of smoking 38 (50%) 36 (47.4%) 74 (48.7%) 0.746
Ongoing smoking 18 (23.7%) 20 (26.3%) 38 (25%) 0.708
Pack-yrs (median) 22.5 25 25 0.415
Cardial disease 12 (15.8%) 14 (18.4%) 26 (17.1%) 0.667
Endocrine diseases 23 (30.3%) 31 (40.8%) 54 (35.5%) 0.175
Diabetes 11 (14.5%) 13 (17.1%) 24 (15.8%) 0.656
ASA score (1/2/3/missing) 3/51/21/1 0/45/28/3 3/96/49/4 0.114
Previous abdominal surgery 17 (22.4%) 15 (19.7%) 32 (21.1%) 0.691
Neoadjuvant chemotherapy 3 (3.9%) 3 (3.9%) 6 (3.9%) 1
Previous abdominal radiation 2 (2.6%) 1 (1.3%) 3 (2%) 0.560
ASA indicates American Society of Anesthesiologists; FEV1, forced expiratory 1-second volume; IPMN, intraductal papillary mucinous neoplasm; mITT, modified intention-to-
treat; VC, vital capacity.
FIGURE 2. Postoperative pancreatic fis-
tula (POPF) incidence and grading in the
study groups.
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TABLE 2. Operative Parameters and Secondary Outcome (mITT)
Coverage (n ¼ 76) No Coverage (n ¼ 76) Total (N ¼ 152) P
Operating time (median, min, range) 155 (70–360) 150 (85–480) 152.5 (70–480) 0.477
Blood loss (median, mL, range) 350 (100–3500) 350 (50–5300) 350 (50–5300) 0.560
Need for transfusion 4 (5.3%) 4 (5.3%) 8 (5.3%) 1
Resection level in relation to portal vein
[meanSD (cm), left-sided in neg.
values]
0.7 (1.8) 0.7 (1.8) 0.7 (1.8) 0.958
Pancreatic transection method 0.832
Scalpel and suture 62 (81.5%) 63 (82.9%) 125 (82.2%)
Stapler 14 (18.4%) 13 (17.1%) 27 (17.8%)
Additional coverage procedure 73 (96.5%) 5 (6.6%) 78 (51.3%) <0.001
Teres ligament 70 (92.1%) 5 (6.6%) 75 (49.3%)
Gastric wall 1 (1.3%) 0 1 (0.7%)
Others 2 (2.6%) 0 2 (1.3%)
Splenectomy 67 (88.2%) 68 (89.5%) 135 (88.8%) 0.797
Cholecystectomy 43 (56.6%) 54 (71.1) 97 (63.3%) 0.063
Extended resection 15 (19.7%) 18 (23.7%) 33 (21.7%) 0.555
Stomach 4 6 10
Liver 3 3 6
Colon 3 8 11
Small bowel 0 3 3
Kidney 0 3 3
Suprarenal gland 7 6 13
Bone 0 1 1
Portal vein 5 4 9
V. cava inferior 1 0 1
Celiac axis 1 0 1
Time until drain removal (d post-OP,
median)
5 5.5 5 0.974
Intra-abdominal collection (patients with
collection/patients with CT-scan)
32/60 (53.3%) 37/66 (56.1%) 69/126 (54.8%) 0.749
Somatostatin post-OP 8 (10.1%) 8 (10.1%) 16 (10.1%) 1
Wound infection 6 (7.9%) 9 (11.8%) 15 (9.9%) 0.418
Abdominal rupture 0 1 (1.3%) 1 (0.7%) 0.321
DGE (A/B/C) 6 (1/3/2; 7.9%) 10 (5/4/1; 13.2%) 16 (6/7/3; 10.5%) 0.353
PPH (A/B/C) 5 (2/2/1; 6.6%) 8 (0/6/2; 10.5%) 13 (2/8/3; 8.6%) 0.222
Discharge with drainage 11 (14.5%) 16 (21.1%) 27 (17.8%) 0.289
Patients with reinterventions 15 (19.7%) 27 (35.5%) 42 (27.6%) 0.030
Patients with reoperation 1 (1.3%) 10 (13.2%) 11 (7.2%) 0.005
Patients with angiography 3 (3.9%) 4 (5.3%) 7 (4.6%) 0.699
Patients with endoscopy and stenting 3 (3.9%) 9 (11.8%) 11 (7.2%) 0.118
Patients with interventional drainage
procedure
12 (15.8%) 21 (27.6%) 33 (21.7%) 0.078
Initial hospital stay (d, median, range) 11.5 (7–128) 12 (6–88) 12 (6–128) 0.843
Patients with need for readmission 10 (13.2%) 24 (31.6%) 34 (22.4%) 0.006
Total inpatient treatment (d, median, range) 12 (7–171) 14.5 (6–88) 13 (6–171) 0.459
Inhospital mortality 0 1 (1.3%) 1 (0.7%) 0.316
post-OP indicates postoperative.
Annals of Surgery  Volume 264, Number 5, November 2016 The DISCOVER Randomized Controlled TrialAs POPF-related complications may occur delayed,6 the
follow-up covered 40 days and 1 year after the index operation.
Interestingly, this late follow-up revealed an additional 20 readmis-
sions after the first follow-up. This observation has merely been
described in other studies19 and raises the question if POPF rates may
have been underestimated in past series with a limited follow-up
time. Recent series are reporting significantly higher POPF rates of
more than 50%.20,21
Apart from the medical impact of POPF and POPF-related
complications, the associated higher healthcare costs of POPF
patients without coverage are an important parameter in the outcome
of DP. Although the cost calculation of the present study is not
directly transferable to other hospitals due to the underlying nation
and region-specific amounts, it can be assumed that the basic effect
of reduced expenses for POPF therapy in the coverage group is Copyright © 2016 Wolters Klu
transferable to other institutions and countries.
 2016 Wolters Kluwer Health, Inc. All rights reserved.The teres ligament patch technique is safe and does not cause
additional expenses or a relevant prolongation of the operation time.
It has also been described to be useful for POPF prevention in
pancreatic enucleations.22 In cases in which the teres ligament patch
is not available for technical reasons (eg, tension due to an increased
distance between abdominal wall and resection margin in obese
patients or due to previous operations), use of gastric or jejunal wall
may be an alternative to cover the pancreatic remnant.11,23 The
supposed effect of the coverage procedure is an encapsulation of
postoperative fluid secretion from the resection margin and preven-
tion of a leakage towards the abdominal cavity. Interestingly, the
drainage fluid did not show differences in secretion volume or
enzyme concentration until postoperative day 4 between both groups.
This may be explained by the process of wound healing, which takes
several days for sealing the remnant by local inflammation andwer Health, Inc. All rights reserved.
adhesion. Especially during the initial phase, fluid secretion can
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TABLE 3. Management of POPF Patients (ITT Population)














(N ¼ 75) P
Patients with reinterventions 9 (25%) 13 (33.3%) 3 (33.3%) 11 (57.9%) 12 (33.3%) 24 (61.5%) 36 (48%) 0.014
Patients with reoperation 1 (2.8%) 6 (15.4%) 0 3 (15.8%) 1 (2.8%) 9 (23.1%) 10 (13.3%) 0.009
Patients with angiography 1 (2.8%) 2 (5.3%) 1 (11.1%) 1 (5.3%) 2 (5.6%) 3 (7.7%) 5 (6.7%) 0.715
Patients with endoscopy and
stenting
2 (5.6%) 6 (15.4%) 0 3 (15.8%) 2 (5.6%) 9 (23.1%) 11 (14.7%) 0.032
Patients with interventional
drainage procedure
7 (19.4%) 10 (25.7%) 3 (33.3%) 9 (47.4%) 10 (27.8%) 19 (48.7%) 29 (38.7%) 0.064
Patients with need for readmission X X X X 9 (25%) 19 (48.7%) 28 (27.3%) 0.034
At least 2 readmissions X X X X 1 (2.8%) 9 (23.1%) 10 (13.3%) 0.009
Hospital stay (d, median, range) 12 (7–90) 15 (6–88) 5 (1–7) 7 (1–21) 15 (7–90) 25 (6–88) 21 (6–90) 0.162
Treatment costs (Euro, median) X X X X 10138 13998 12737 0.035
Hassenpflug et al Annals of Surgery  Volume 264, Number 5, November 2016occur, which is finally stopped by the sealing effect. This pathophy-
siological mechanism may provide an additional explanation why the
overall incidence of POPF—which is defined as a leakage on or after
postoperative day 3—may not be altered by the procedure.
In the follow-up imaging, postoperative fluid collections at the
resection site were observed in more than 50% of the patients. We
have recently reported this high incidence of fluid collections after
DP.24 The vast majority of these collections are not clinically
relevant. However, in patients who required drainage, amylase
concentration of the fluid contained in these collections differed
between covered and uncovered patients with remarkably lower
amylase values after the coverage procedure. This gives another
explanation for the observed divergent postoperative courses of
fistula patients in both groups.
A recent randomized controlled trial in which a thin flap of the
falciforme ligament was detached and sutured to the resection margin
did not find any effect on POPF rate or on the postoperative course.25
Supposedly, a devascularized and rather small flap might be more
prone to atrophy and necrosis during the postoperative period when
sealing process takes place. A pedicled and vascularized flap, which
was used in our DISCOVER trial, may be more effective.
In the present study, all procedures were carried out as open
DPs according to the study protocol, which was drafted during a
period of time when the laparoscopic approach was not yet regarded
as the standard for DP. A laparoscopic use of the teres ligament patch
technique is certainly possible as well. To date, there are no studies
available for this approach. Based on the results of the DISCOVER
trial, this technique should also be evaluated in laparoscopic DP as
the problem of POPF is an unsolved issue in this setting as well.26
CONCLUSIONS
Coverage of the pancreatic remnant during DP is associated
with less postoperative reinterventions, reoperations, and less need
for readmission. Although overall fistula rate is not reduced by the
coverage procedure, it should be considered as a valid possibility to
prevent complications after DP as it is easy to perform and shows a
clinical benefit.
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DISCUSSANTS
O. Farges (Clichy, France):
I congratulate you and your group for the persistent effort in
finding technical ways to reduce the incidence of pancreatic fistula
and for the quality of your presentation. I have 3 questions: First, this
is an intent-to-treat analysis, but I notice that 8 patients (3 in the study
group and 5 in the control group) did not receive the treatment they
should have received. Do the results of the study change if patients
are allocated to the treatment actually received or are excluded from
analysis? Second, how many surgeons were involved and how did
you ensure that the coverage procedure had been done properly? As
this is a concern common to trials focusing on a technique, don’t you
think that, in the future, a picture should be taken at the end of
surgery? Third, the main difference in the 2 groups is a reduced
incidence of reoperation and of readmission in the study group. Both
endpoints are somewhat subjective. As this is an open (not a blinded)
study and since the previous study from your group showed that
coverage of the pancreatic remnant decreased clinically relevant
fistula, is there a risk that management was more conservative in the
study group than in the control group?
Response From T. Hackert (Heidelberg, Germany):
We had this problem as 5 and 3 cross-over patients were not
treated according to the protocol in each group. I think this problem
can occur in every clinical study: that the patient is not compliant or
the surgeon is not compliant. We did the intention-to-treat analysis
because this was stated in the study protocol which I presented to
you. After this point came up, during the revision of the manuscript,
we also did an internal per-protocol analysis. This analysis basically
showed the same results, which shows that the study was not very
much influenced by these 3 and 5 patients.
I think the second question is an important topic in all surgical
studies. We basically had 8 surgeons who were responsible during the
study period between 2010 and 2014. We intended to take a
photograph of every operation which was also stated in the study
protocol and should have been done. Finally, we ended up with
approximately 80% of photographs. In 20% of the patients, photo-
graphs were not present, but surgeons had to fill in an evaluation form
after the operation and state that ‘‘yes, I did coverage’’ or ‘‘no, I did
no coverage.’’ In addition, the resection margin in relation to the
portal vein was also documented.
I do not think fistula management was a bias, because the
indication for an intervention or the indication for a reoperation
should not be based on any study you just perform currently or that
you think it will not become that severe. I think the clinical Copyright © 2016 Wolters Klu
impression of the patient is what leads to the decision of ‘‘yes, he
 2016 Wolters Kluwer Health, Inc. All rights reserved.needs a drainage’’ or ‘‘no, he needs no drainage,’’ and not any other
confounding consideration.
N. Senninger (Münster, Germany):
You are creating a new gap by bending the teres ligament to
the pancreas. Has this gap ever been producing interceptional power?
I thought Heidelberg was a nondraining clinic. Did you change
your strategy?
The omentum is next to it, and has much more important cells
than this little fat pad of the teres ligament. Why did not you choose
the teres ligament? By the way, many have tried that before and there
was no benefit.
Response From T. Hackert (Heidelberg, Germany):
Regarding the ‘‘gap’’ that we create, of course there is the
theoretical possibility that there might be some herniation. This is
something we have never observed because it is located only in the
upper abdominal space below the liver on the right side. I think the
small bowel will not really come there by going behind the stomach.
We had no revisions because of a problem like that.
We routinely place passive drainage tubes intraoperative after
distal pancreatectomy is routinely drained as it was performed in the
study. To use the omentum is of course a good possibility; however, I
think the omentum does not have this tight and firm surface which the
teres ligament has. The coverage material from the teres ligament-
from my experience-is more suitable than the omentum, which is
often a bit crispy and not solid. This does not nearly fit that well to
cover the pancreatic cut surface.
C. Bruns (Cologne, Germany):
Was the texture of the pancreas only intraoperatively eval-
uated? For pancreatic stump closure, which technique did you allow:
stapler or conventional surgical cutting and suturing, or any of them?
Was the decision about the closure technique made intraoperatively?
Response From T. Hackert (Heidelberg, Germany):
The texture of the pancreas was evaluated intraoperatively;
however, we did not document the texture in the study protocol. This
may be a little shortcoming of the study.
Regarding the choice for stapler application, this was free to
every surgeon. By that time we had used this adaptable stapler, which
may also be suitable for a thicker pancreas, but actually for thick
pancreas probably most surgeons choose to cut it by scalpel and close
the cut margin by suture. Furthermore, crushing of the pancreas or
squeezing the pancreas might cause a fistula and a hematoma when the
stapler is not suitable due to the thickness of the parenchyma.
A. Sauvanet (Clichy, France):
One of the well-known risk factors of pancreatic fistula after
distal pancreatic is body mass index (BMI). I did not notice that the
BMI was strictly equivalent between both groups. My second ques-
tion is about the way you plan the postoperative course after
discharge. What was the proportion of patients who went back home,
who went to other hospitals or other facilities? Was the course after
hospital stay equivalent between the groups? It could have influenced
the rate of readmission and the rate of reintervention, particularly
interventional radiology.
Response From T. Hackert (Heidelberg, Germany):
The BMI was analyzed and it was not a confounding factor in
the analysis, which is shown in the manuscript. The discharge policy
of course plays a role for the readmission. Basically we tried
to discharge the patients when they had no drain anymore in eitherwer Health, Inc. All rights reserved.
group, no matter if covered or not covered. Of course, sometimes
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cause another readmission, as well as readmission without drainage
was included when necessary for an additional new drainage. This
policy, I think, was similar in both groups.
A. Olah (Györ, Hungary):
The reoperation rate was slightly high in the control group,
more than 13%. What was the major indication for the reoperation?
Recently, we tried to increase the rate of laparoscopic distal pan-
createctomy. Do you have any experience with this technique
laparoscopically or only in open surgery?
Response From T. Hackert (Heidelberg, Germany):
Regarding the rate of reoperation, we had 13% in the
controlgroup without coverage. Except for 1 patient, they were
all fistula-associated, which means due to bleeding, due to
infection control, due to any problems associated with a pancreatic
fistula such as bowel perforation. I think this was quite impressive
as in the teres group we only had 1 reoperation for fistula-
associated reasons.
Regarding the laparoscopic approach, we have, of course, in Copyright © 2016 Wolters Kluw
730 | www.annalsofsurgery.comprocedure. We have not yet performed the teres ligament patch
laparoscopically, although this might be possible as well.
T. van Gulik (Amsterdam, The Netherlands):
You showed no significant differences in the rate of inter-
ventions required in the teres ligament patch group and no-coverage
group. Regarding the protective effects of the teres ligament patch,
do you think that it really prevents leakage or does it contain leakage?
In other words, does coverage conceal leakage to result in less
problems that need an intervention? The only way you could tell
if that is the mechanism is by checking on follow-up imaging in
these patients.
Response From T. Hackert (Heidelberg, Germany):
That’s a very good question because we see a lot of fluid
collections without a clinical impact after distal pancreatectomy of
any kind. I think that from the mechanism, the teres ligament might
cover, attach, and maybe have a fluid collection below it. This is
usually not clinically relevant and does not cause any problems. As I
showed you with regard to the peak amylase values, there is a certain
leakage, of course, but it is not that severe as when the pancreatic
remnant is not covered.the meantime standardized distal pancreatectomy as a laparoscopicer Health, Inc. All rights reserved.
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